Mitchell Ho, Senior Investigator and Deputy Chief, Laboratory of Molecular Biology at National Cancer Institute (NCI) shared a post on LinkedIn:
“I’m excited to share that I’ll be speaking about our work on engineering of CAR T cells targeting glypican-2 (GPC2) for childhood cancers at CHI’s PEGS Boston Summit, May 12, 2026 in Boston, MA. Hope to see you there!”
Other articles about CAR T Cells on OncoDaily.